This double-blind randomized controlled study was designed to evaluate the analgesic effects of topical treatments with clonidine (CLON) and pentoxifylline (PTX) tested alone or as low- and high-dose combinations in a human experimental model of pain. Of 69 healthy subjects aged 18 to 60 years, 23 each were randomly allocated to low-dose (0.04% + 2%) and high-dose (0.1% + 5%) CLON + PTX groups. Both of these groups also received their corresponding placebos in one of 2 treatment periods separated by at least 48 hours. Twenty-three additional subjects received either CLON (0.1%) or PTX (5%) as single drug treatments, in each of 2 treatment periods. Assessment of analgesic efficacy was based on allodynic effects of previous intraepidermal capsaicin injection, as well as postcapsaicin tourniquet-induced pain 50 minutes following capsaicin injection. Visual Analogue Scale (VAS) ratings of pain intensity and the area of dynamic mechanical allodynia were the primary outcome measures, whereas area of punctate mechanical allodynia (PMA) served as a secondary outcome measure. Topical treatments with high- or low-dose combinations significantly reduced VAS ratings compared with corresponding placebo treatments throughout the period of postcapsaicin tourniquet-induced pain. Importantly, the high-dose combination produced lower VAS ratings than CLON alone, which were lower than PTX alone. Results also revealed significant inhibition of postcapsaicin dynamic mechanical allodynia and PMA for the high-dose combination compared with placebo, and of PMA for CLON compared with the low-dose combination. Hence, the present data are supportive of further clinical investigation of the high-dose topical combination of CLON + PTX in complex regional pain syndrome and neuropathic pain patients, for which our preclinical data predict efficacy.
Topical combination of clonidine and pentoxifylline, more effectively than single agents alone, alleviates postcapsaicin tourniquet-induced pain, as well as capsaicin-induced allodynia, in healthy human volunteers.
aDepartment of Anesthesia, McGill University, Montreal, QC, Canada
bAlan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada
cFaculty of Dentistry, McGill University, Montreal, QC, Canada
dMcGill University Hospital Centre Research Institute, Montreal, QC, Canada
eAlan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
fAntiva Biosciences, Inc, South San Francisco, CA, USA
Departments of gNeurology & Neurosurgery and
hPsychology, McGill University, Montreal, QC, Canada
*Corresponding author. Address: Anesthesia Research Unit, 1203-3655 Promenade Sir William Osler, Montreal, QC, H3G 1Y6, Canada. Tel.: 1 514 398 5773. E-mail address: firstname.lastname@example.org (T.J. Coderre).
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.painjournalonline.com).